Merck & Co. (MRK)
(Delayed Data from NYSE)
$102.32 USD
-2.51 (-2.39%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $102.65 +0.33 (0.32%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$102.32 USD
-2.51 (-2.39%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $102.65 +0.33 (0.32%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data
by Zacks Equity Research
A mid-stage study data shows that Immutep's (IMMP) lead candidate as a combination therapy in first-line NSCLC achieved better-than-expected overall survival results.
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why
by Zacks Equity Research
Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.
The Zacks Analyst Blog Highlights UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International
by Zacks Equity Research
UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International are part of the Zacks top Analyst Blog.
Top Research Reports for UnitedHealth Group, Merck & Texas Instruments
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Merck & Co., Inc. (MRK) and Texas Instruments Incorporated (TXN).
Should ALPS O'Shares U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OUSA
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance
by Zacks Equity Research
Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.
Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study
by Kinjel Shah
Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.
Seagen's (SGEN) Q1 Earnings and Revenues Miss Expectations
by Zacks Equity Research
Seagen (SGEN) reports worse-than-expected results in the first quarter of 2023, missing both earnings and sales estimates.
Company News for Apr 28, 2023
by Zacks Equity Research
Companies In The News Are: MA, MRK, SO, NOC.
Moderna (MRNA) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investors focus will likely be on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports first-quarter earnings.
Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View
by Zacks Equity Research
Merck (MRK) beats Q1 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales
by Zacks Equity Research
AstraZeneca (AZN) beats first-quarter estimates for earnings while missing the same for sales. The company reaffirms its 2023 guidance.
Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 4.48% and 4.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings
by Mark Vickery
Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.
Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More
by Ahan Chakraborty
Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.
Healthcare: An Essential Sector (3 Stocks to Buy Ahead of Earnings)
by Andrew Rocco
Healthcare stocks are an excellent place to park your money in the current market environment. Due to it's necessity, the sector tends to due well in any economy.
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
Zacks Investment Ideas feature highlights: Nasdaq 100 ETF, Dexcom, Merck, Intuitive Surgical and SPDR S&P Regional Bank ETF
by Zacks Equity Research
Nasdaq 100 ETF, Dexcom, Merck, Intuitive Surgical and SPDR S&P Regional Bank ETF have been highlighted in this Investment Ideas article.